

**RECORDATI: PUBLICATION OF DOCUMENTS RELATING TO THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS CALLED FOR 29.04.2025**

Milan, 24<sup>th</sup> March 2025 - Please be informed that the following reports approved by the Board of Directors of Recordati S.p.A. on 18<sup>th</sup> March 2025:

- (i) the **Report on the 2025 Remuneration policy and the remuneration paid for 2024**;
- (ii) the **Directors' Reports relating to the following items of the agenda of the Ordinary Shareholders' Meeting** called for the 29<sup>th</sup> April 2025:
  - item no. 3 (Report on the Remuneration policy and the remuneration paid) which includes, as its annex, the Report on Remuneration policy and the remuneration paid referred to in point (i); and
  - item no. 4 (Authorization to the purchase and disposal of treasury stock),

are available to the public, as of today, at the Company's registered office and published on the Company's website ([www.recordati.it](http://www.recordati.it), the first report in the Governance - Remuneration section; and the other reports in the Investors - Shareholder Information section) and on the '1INFO' storage mechanism ([www.1info.it](http://www.1info.it)).

***Recordati** is an international pharmaceutical group listed on the Italian Stock Exchange (XMil: REC), with roots dating back to a family-run pharmacy in Northern Italy in the 1920s. We are uniquely structured to provide treatments across specialty and primary care, and rare diseases. Our fully integrated operations span clinical development, chemical and finished product manufacturing, commercialization and licensing. We operate in approximately 150 countries across EMEA, the Americas and APAC with over 4,450 employees. We believe that health is a fundamental right, not a privilege. Today, our purpose of "unlocking the full potential of life" aims at empowering individuals to live life to the fullest, whether addressing common health challenges or the rarest.*

**Investor Relations**

Eugenia Litz  
+44 7824 394 750  
[investorelations@recordati.it](mailto:investorelations@recordati.it)

Gianluca Saletta  
+39 348 979 4876  
[investorelations@recordati.it](mailto:investorelations@recordati.it)

**Media Relations**

ICR Healthcare US:  
Alexis Feinberg  
[+1 203 939 2225](tel:+12039392225)  
[recordatiuspr@westwicke.com](mailto:recordatiuspr@westwicke.com)

UK, Europe & Rest of World:  
Jessica Hodgson  
+44 7561 424 788  
[recordati@consilium-comms.com](mailto:recordati@consilium-comms.com)

**RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.**

Registered Office  
Via Matteo Civitali, 1  
20148 Milano, Italy  
Tel. +39 02 487871  
Fax +39 02 40073747  
[www.recordati.com](http://www.recordati.com)

Share Capital € 26.140.644,50 fully paid-up  
Milano, Monza, Brianza and Lodi Comp. Reg. No. 00748210150  
Tax Code/VAT No. 00748210150  
Milano R.E.A. No. 401832

Company subject to the Management and Coordination Activity of Rossini Luxembourg S.à.r.l